The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation.

The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Abstract Text:

AG 879 has been widely used as a Tyr kinase inhibitor specific for ErbB2 and FLK-1, a VEGF receptor. The IC(50) for both ErbB2 and FLK-1 is around 1 microM. AG 879, in combination of PP1 (an inhibitor specific for Src kinase family), suppresses almost completely the growth of RAS-induced sarcomas in nude mice. In this paper we demonstrate that AG 879 even at 10 nM blocks the specific interaction between the Tyr-kinase ETK and PAK1 (a CDC42/ Rac-dependent Ser/Thr kinase) in cell culture. This interaction is essential for both the RAS-induced PAK1 activation and transformation of NIH 3T3 fibroblasts. However, AG 879 at 10 nM does not inhibit either the purified ETK or PAK1 directly in vitro, suggesting that this drug blocks the ETK-PAK1 pathway by targeting a highly sensitive kinase upstream of ETK. Although the Tyr-kinases Src and FAK are known to activate ETK directly, Src is insensitive to AG 879, and FAK is inhibited by 100 nM AG 879, but not by 10 nM AG879. The structure-function relationship analysis of AG 879 derivatives has revealed that both thio and tert-butyl groups of AG 879, but not (thio) amide group, are essential for its biological function (blocking the ETK-PAK1 pathway), suggesting that through the (thio) amide group, AG 879 can be covalently linked to agarose beads to form a bioactive affinity ligand useful for identifying the primary target of this drug.

The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer biology & therapy

VOLUME: 3

Page Numbers: 96-101

Journal Abbreviation: Cancer Biol. Ther.

ISSN: 1538-4047

DAY: 29

MONTH: 01

YEAR: 2004

The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101137842

The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Keywords Mesh Terms:

KEYWORDS: ras Proteins

MESH TERMS: antagonists & inhibitors

Chemical & Substance for Abstract: The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Information

Substance Name: ras Proteins

Registry Number: EC 3.6.5.2

Grant and Affiliation Information for The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation.

AFFILIATION: Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville/Melbourne, Australia.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Biol Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation Related Publications

• An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
• Analysis of the conformational change of myosin during ATP hydrolysis using fluorescence resonance energy transfer.
• Atypical depression as a premonitory symptom of migraine managed by an oral contraceptive.
• Chirped nonlinear pulse propagation in a dispersion-compensated system.
• Conformational change of the loop L5 in rice kinesin motor domain induced by nucleotide binding.
• Depression associated with chronic pain: incidence, characteristics, and long-term outcome.
• Effect of abdominal surgery on glucose tolerance, plasma levels of insulin and glycogenic amino acids.
• Formation and characterization of kinesin.ADP.fluorometal complexes.
• Incorporation of an azobenzene derivative into the energy transducing site of skeletal muscle myosin results in photo-induced conformational changes.
• Intermolecular cross-linking of a novel rice Kinesin k16 motor domain with a photoreactive ATP derivative.
• Optimal design of dispersion management for a soliton wavelength-division-multiplexed system.
• PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition.
• Photocontrol of Kinesin ATPase activity using an azobenzene derivative.
• Preparation and characterization of a novel rice plant-specific kinesin.
• Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation.
• Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.
• The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants.
• The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation.